In the article “Different Toxicity of Cetuximab and Panitumumab in Metastatic Colorectal Cancer Treatment: A Systematic Review and Meta-Analysis” [Oncology 2018;94(4):191–199, https://doi.org/10.1159/000486338] by Fausto Petrelli et al., the number of reported trials was listed incorrectly as “38” instead of “37” in the Abstract, Results, and Discussion sections, as well as in Figure 1. The error arose because one study [1] was counted twice, as the study was included in both groups as it compared panitumumab and cetuximab. The authors stated that there are no ramifications for this, as toxicities were counted only once for each arm. The corrected Figure 1 is shown here.

Fig. 1.

Flowchart of included studies.

Fig. 1.

Flowchart of included studies.

Close modal
1.
Price TJ, Peeters M, Kim TW, et al: Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, noninferiority phase 3 study. Lancet Oncol 2014;15:569–579.